Back to results
US 7,972,843 B2Granted
DNA-transfection system for the generation of infectious influenza virus
AssigneeSt. Jude Children's Research Hospital
InventorErich Hoffmann
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorErich Hoffmann
Estimating the term…
The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
A composition comprising a set of plasmids, which results in assembly of an infectious segmented negative strand RNA virus upon introduction in a host cell, wherein each plasmid of said set comprises one viral genomic segment of a negative strand RNA virus, and wherein the viral cDNA corresponding to the viral genomic segment is inserted between an RNA polymerase I (pol I) promoter and a regulatory element, which results in expression of vRNA or cRNA with an exact 3′ end, which are in turn inserted between an RNA polymerase II (pol II) promoter and a polyadenylation signal, which results in expression of viral mRNA and a corresponding viral protein, wherein the expression of vRNAs or cRNAs and viral proteins from said set of plasmids results in an infectious segmented negative strand RNA virus and wherein the total number of the plasmids in said composition does not exceed the total number of the gene segments of said negative strand RNA virus.
A composition comprising a set of plasmids, which results in assembly of a segmented negative strand RNA virus upon introduction in a host cell, wherein each plasmid of said set comprises one viral genomic segment of a negative strand RNA virus, and wherein the viral cDNA corresponding to the viral genomic segment is inserted between an RNA polymerase I (pol I) promoter and a regulatory element, which results in expression of vRNA or cRNA with an exact 3′ end, which are in turn inserted between an RNA polymerase II (pol II) promoter and a polyadenylation signal, which results in expression of viral mRNA and a corresponding viral protein, wherein the expression of vRNAs or cRNAs and viral proteins from said set of plasmids results in a segmented negative strand RNA virus, which is adapted to grow well in culture, attenuated, or pathogenic, wherein the total number of the plasmids in said composition does not exceed the total number of the gene segments of said negative strand RNA virus, and wherein at least one of the viral genomic segments contain one or more mutations.
Dependencies are inferred from the claim text.